Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than ...
Jun 8, 2012
0
0